Publication Name	World Journal of Hepatology
Manuscript ID	13941
Country	Italy

Received	2014-09-09 12:19
Peer-Review Started	2014-09-09 20:51
To Make the First Decision	2014-10-14 17:31
Return for Revision	2014-10-20 08:10
Revised
Second Decision	2014-12-10 11:31
Accepted by Journal Editor-in-Chief	2014-12-13 23:43
Accepted by Company Editor-in-Chief	2014-12-17 16:22
Articles in Press	2014-12-17 16:22
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-03-20 12:12
Publish the Manuscript Online	2015-03-31 15:58

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs
Manuscript Source	Invited Manuscript
All Author List	Francesca De Nard, Monica Todoerti, Vittorio Grosso, Sara Monti, Silvia Breda, Silvia Rossi, Carlomaurizio Montecucco and Roberto Caporali
Funding Agency and Grant Number
Corresponding Author	Francesca De Nard, MD, IRCCS Policlinico San Matteo Foundation, Chair and Division of Rheumatology, University of Pavia, piazzale Golgi 2, 27100 Pavia, Italy. francesca.denard01@ateneopv.it
Key Words	Rheumatoid arthritis; Hepatitis B virus; Biologics; Anti-TNF; Rituximab; Tocilizumab; Abatacept
Core Tip	Hepatitis B virus (HBV) infection represents a major issue in patients with rheumatoid arthritis (RA) undergoing biological disease-modifying anti-rheumatic drugs (bDMARDs). While several observational studies and trials deal with the risk of HBV reactivation under anti-TNF agents, there is limited experience with newer drugs as tocilizumab (TCZ) and abatacept (ABA). In this paper, literature concerning the risk of HBV reactivation in RA patients undergoing different classes of bDMARDs, including ABA and TCZ, has been revised. Finally, some evidence-based practical suggestions for the management of this condition are proposed.
Publish Date	2015-03-31 15:58
Citation	De Nard F, Todoerti M, Grosso V, Monti S, Breda S, Rossi S, Montecucco C, Caporali R. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. World J Hepatol 2015; 7(3): 344-361
URL	http://www.wjgnet.com/1948-5182/full/v7/i3/344.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i3.344

Full Article (PDF)	WJH-7-344.pdf
Full Article (Word)	WJH-7-344.doc
Manuscript File	13941-Review.doc
Answering Reviewers	13941-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	13941-Conflict-of-interest.pdf
Copyright License Agreement	13941-Copyright assignment.pdf
Peer-review Report	13941-Peer review(s).pdf
Scientific Misconduct Check	13941-CorssCheck.jpg
Scientific Editor Work List	13941-Scientific editor work list.pdf